ClinicalTrials.Veeva

Menu
S

South Texas Accelerated Research Therapeutics | START Midwest

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Nivolumab
Hu5F9-G4
SL-172154
PF-07220060
PF-07104091
ABBV-400
Carboplatin
Budigalimab
SM08502

Parent organization

This site is a part of South Texas Accelerated Research Therapeutics

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

73 of 108 total trials

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

Active, not recruiting
HER2-positive Endometrial Cancer
HER2-positive Colorectal Cancer
Drug: BDC-1001
Drug: Nivolumab

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary...

Enrolling
Metastatic Solid Tumor
Drug: Pembrolizumab
Drug: PLN-101095

This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.

Enrolling
Advanced Solid Tumors
Drug: RO7623066
Drug: Olaparib

This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept effi...

Enrolling
Metastatic Skin Cancer
Melanoma Stage IV
Drug: Fruquintinib
Drug: FOLFIRI regimen & bevacizumab

This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy o...

Enrolling
Breast Cancer
Glioblastoma
Drug: Temozolomide
Drug: ST101

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

Enrolling
Transitional Cell Carcinoma of Bladder
High Grade Serous Adenocarcinoma of Ovary
Drug: VLS-1488

This study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no...

Active, not recruiting
Solid Tumor, Adult
Drug: SM08502

This study is an open-label, multi-center, dose-escalation, dose expansion study in adult subjects with advanced solid tumors. The study will evaluat...

Active, not recruiting
Non-small Cell Lung Cancer
Castration-resistant Prostate Cancer
Drug: SM08502
Drug: Prednisone

This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single...

Active, not recruiting
Advanced Cancer
Drug: a PD-1 inhibitor
Drug: AGEN1777

The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a re...

Enrolling
Advanced Cancer
Drug: Docetaxel
Drug: Zimberelimab

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patie...

Enrolling
Solid Tumors
Drug: ADRX-0706
Locations recently updated

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of a...

Enrolling
Advanced or Metastatic Colorectal Cancer
Biological: Leucovorin
Biological: Fluorouracil

ASP2074 is a potential new treatment for people with certain solid tumors. Before ASP2074 is available as a treatment, the researchers need to unders...

Active, not recruiting
Advanced Solid Tumors
Drug: ASP2074

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benef...

Active, not recruiting
Advanced Solid Tumors
Non-small Cell Lung Cancer
Drug: Carboplatin
Drug: Pemexetred

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumor...

Enrolling
Advanced Solid Tumor
Drug: CLN-619
Drug: Pembrolizumab

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209...

Enrolling
Endometrial Cancer
Lymphoma, T-Cell
Drug: CPI-0209

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anti...

Enrolling
GIST
Drug: Ripretinib
Drug: DCC-3116

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelod...

Active, not recruiting
Higher Risk Myelodysplastic Syndromes
Drug: evorpacept
Drug: azacitidine

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of JNJ-78278343 and combination agent in Part 1 (dose escalation)...

Enrolling
Metastatic Castration-resistant Prostate Neoplasms
Drug: Cabazitaxel
Drug: Enzalutamide
Locations recently updated

The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D...

Enrolling
Advanced Solid Tumors
Drug: JNJ-87890387

Trial sponsors

Pfizer logo
AbbVie logo
Gilead Sciences logo
Ascentage Pharma Group logo
C
I
Janssen (J&J Innovative Medicine) logo
MacroGenics logo
S
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems